These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 25397417)

  • 21. Low-level HIV-1 viraemia in patients on HAART: risk factors and management in clinical practice.
    Wirden M; Todesco E; Valantin MA; Lambert-Niclot S; Simon A; Calin R; Tubiana R; Peytavin G; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2015 Aug; 70(8):2347-53. PubMed ID: 25921516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Predictive factors of viral load high-risk events for virological failure in HIV/AIDS patients receiving long-term antiviral therapy.
    Qin S; Lai J; Zhang H; Wei D; Lv Q; Pan X; Huang L; Lan K; Meng Z; Liang H; Ning C
    BMC Infect Dis; 2021 May; 21(1):448. PubMed ID: 34006230
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral therapy (ART) management of Low-Level Viremia in Taiwan (ALLEVIATE).
    Cheng CY; Luo YZ; Wu PY; Liu WC; Yang SP; Zhang JY; Cheng SH; Hung CC
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19785. PubMed ID: 25397529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of associations and development of atazanavir resistance after unplanned treatment interruptions.
    Tinago W; O'Halloran JA; O'Halloran RM; Macken A; Lambert JS; Sheehan GJ; Mallon PW
    HIV Med; 2014 Apr; 15(4):224-32. PubMed ID: 24215370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Persistent low-level HIV-1 RNA between 20 and 50 copies/mL in antiretroviral-treated patients: associated factors and virological outcome.
    Charpentier C; Landman R; Laouénan C; Joly V; Hamet G; Damond F; Brun-Vézinet F; Mentré F; Descamps D; Yeni P
    J Antimicrob Chemother; 2012 Sep; 67(9):2231-5. PubMed ID: 22643190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low level HIV viremia is more frequent under protease-inhibitor containing firstline therapy than under NNRTI-regimens.
    Wiesmann F; Braun P; Knickmann M; Knechten H
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19828. PubMed ID: 25397572
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Outcomes following detection of low level plasma HIV RNA in HIV-infected patients previously virologically suppressed on antiretroviral therapy: a retrospective observational study.
    Warren AM; Cheng AC; Watson K; Lewin SR; Hoy JF
    Sex Health; 2017 Jun; 14(3):238-243. PubMed ID: 28445685
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Service impact of a change in HIV-1 viral load quantification assay.
    Tipple C; Oomeer S; Dosekun O; Mackie N
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19677. PubMed ID: 25397427
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment.
    Elvstam O; Medstrand P; Yilmaz A; Isberg PE; Gisslén M; Björkman P
    PLoS One; 2017; 12(7):e0180761. PubMed ID: 28683128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased risk of virological failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort.
    Saracino A; Lorenzini P; Lo Caputo S; Girardi E; Castelli F; Bonfanti P; Galli M; Caramello P; Abrescia N; Mussini C; Monno L; Monforte Ad
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19769. PubMed ID: 25397513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevalence of drug resistance mutations in HIV-infected individuals with low-level viraemia under combination antiretroviral therapy: an observational study in a tertiary hospital in Northern Taiwan, 2017-19.
    Kao SW; Liu ZH; Wu TS; Ku SW; Tsai CL; Shie SS; Huang PY; Wu YM; Hsiao YH; Chen NY
    J Antimicrob Chemother; 2021 Feb; 76(3):722-728. PubMed ID: 33331635
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.
    Geretti AM; Smith C; Haberl A; Garcia-Diaz A; Nebbia G; Johnson M; Phillips A; Staszewski S
    Antivir Ther; 2008; 13(7):927-36. PubMed ID: 19043927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. INSTI-Based Triple Regimens in Treatment-Naïve HIV-Infected Patients Are Associated With HIV-RNA Viral Load Suppression at Ultralow Levels.
    Lambert-Niclot S; Boyd A; Fofana D; Valin N; Wirden M; Meynard JL; Palich R; Agher R; Valantin MA; Calvez V; Katlama C; Girard PM; Marcelin AG; Morand-Joubert L
    Open Forum Infect Dis; 2019 May; 6(5):ofz177. PubMed ID: 31123690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcomes of persistent low-level viremia among HIV patients on antiretroviral therapy: A prospective cohort study.
    Ding H; Xu J; Liu J; Wang Q; Kang J; Li X; Zhang Z; Han X; Jiang Y; Geng W; Shang H
    HIV Med; 2022 Mar; 23 Suppl 1():64-71. PubMed ID: 35293103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
    J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Four-drugs regimen containing raltegravir is highly effective in HIV patients starting therapy with >500,000 copies/mL viral load.
    Sterrantino G; Zaccarelli M; Prati F; Boschi A; Sighinolfi L; Borghi V
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19774. PubMed ID: 25397518
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-level viral loads and virological failure in the integrase strand transfer era.
    Cuzin L; Flandre P; Allavena C; Palich R; Duvivier C; Becker A; Laroche H; Pugliese P; Cabie A;
    J Antimicrob Chemother; 2023 Apr; 78(4):1111-1116. PubMed ID: 36879512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of HIV-1 drug resistance in treatment-naïve patients and its clinical implications in an antiretroviral treatment program in Cameroon.
    Zoufaly A; Jochum J; Hammerl R; Nassimi N; Raymond Y; Burchard GD; Schmiedel S; Drexler JF; Kay CN; Taka N; Awasom C; Metzner K; Jan vL; Feldt T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19615. PubMed ID: 25394119
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and socio-demographic predictors for virologic failure in rural Southern Africa: preliminary findings from CART-1.
    Labhardt ND; Bader J; Ramoeletsi M; Kamele M; Lejone TI; Cheleboi M; Motlatsi MM; Ehmer J; Faturyiele O; Puga D; Klimkait T
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19666. PubMed ID: 25397416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.